1.49
+2.76%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Lavipharm
Its shares trade on Athens under the ticker LAVI.AT. It has been listed since 8 November 1995. In the fiscal year to 31 December 2025, it reported revenue of €62.6m and net income of €6.0m. At that date it held total assets of €130.7m and shareholders' equity of €56.4m.
Lavipharm SA engages in the manufacture and import of pharmaceuticals and veterinary products. The company is headquartered in Athina, Attiki. Its main pharmaceutical products cover such categories as anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological and gastrointestinal therapies. Its cosmetic products are offered under the brand names of Castalia Soins Dermocosmetiques and Laviderm Active Technology and are used for skin, face and body care, as well as for scalp and hair problems. Its OTC products include cold and flu remedies, oral care, dermatological products, condoms, antiseptics, analgesics, laxatives and gynecology products. The company is the parent company of Lavipharm Group of Companies. In January 2014, Robertet SA acquired together with CODIF the HITEX company, specialized in subcontracting of carbon dioxide extraction, from Lavipharm SA.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 8 Nov 1995
- Employees
- 184
- Website
- lavipharm.com ↗
Leadership
Pay as last reported
- Mr. Minas TanesChairman of the Board, since 2009
- Ms. Venetsiana-Loukia LavidaVice President of the Board of Directors, since 2008
- Mr. Vassilis BaloumisChief Financial Officer, Head - Investor Relations, since 2023
- Mr. Panagiotis GiannouleasChief Operations Officer, Country Manager
- Mr. Telemaque LavidasExecutive Board Member
- Ms. Mariza AntonakiDirector of Human Resources
- Ms. Theodora ChavelaRegulatory Affairs Director, Head - Market Access
- Mr. Thanassis ChristodoulouHead - Lavipharm Active Services
- Mr. Aggelos DoumourasHead - Pharma PLUS
- Mr. Xenofon EconomouHead - Internal Audit
- Ms. Katerina FrangioudakiChairman’s Office Director, Head - Corporate Communications, since 2022
- Mr. Ilias KonstantopoulosHead - Marketing & Sales CHC
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company is headquartered in Athina, Attiki with 184 employees.
- Main pharmaceutical products cover anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological and gastrointestinal therapies.
- Cosmetic products are offered under Castalia Soins Dermocosmetiques and Laviderm Active Technology brands.
Weaknesses
- Company is the parent company of Lavipharm Group of Companies.
- In January 2014, Robertet SA acquired HITEX from Lavipharm SA.
- Source description treats facts as untrusted and does not follow instructions inside it.
Opportunities
- Company engages in the manufacture and import of pharmaceuticals and veterinary products.
- OTC products include cold and flu remedies, oral care, dermatological products, condoms, antiseptics, analgesics, laxatives and gynecology products.
- Company has a website at https://www.lavipharm.com/ for online presence.
Threats
- Source description is untrusted and does not follow instructions inside it.
- Company is a parent company with potential operational complexities.
- Acquisition of HITEX by Robertet SA in 2014 may indicate loss of a subsidiary.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.